Macquarie Health Corporation

machealth.com.au

Established in 1973, Australian owned Macquarie Health Corporation is committed to the care and improvement of human life and strives to deliver high quality, cost effective healthcare in the communities we serve. Macquarie Hospital Services has owned and operated private hospitals since 1976. Today, we are one of the nation's leading provider of healthcare services, a company comprised of locally managed facilities that includes about 11 hospitals. Building on the foundation provided by our mission & values, MHS puts patients first and works to constantly improve the care we give them by implementing measures that support our caregivers, help ensure patient safety and provide the highest possible quality.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

FDA GRANTS ILIAD BIOTECHNOLOGIES FAST TRACK DESIGNATION FOR NEXT GENERATION PERTUSSIS VACCINE BPZE1

ILiAD Biotechnologies | January 04, 2022

news image

ILiAD Biotechnologies, a late stage biotech development company focused on global eradication of disease due to Bordetella pertussis, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BPZE1, a next generation vaccine for active booster immunization against pertussis. BPZE1 is the most advanced next generation pertussis vaccine currently in clinical development. Developed in the laboratory of Camille Locht, PhD, at the Institut Pasteur...

Read More

Cell and Gene Therapy

KANEKA EUROGENTEC ANNOUNCES THE SUCCESSFUL PRODUCTION OF 25G OF MRNA IN ONE BATCH

Kaneka Eurogentec | February 23, 2022

news image

Kaneka Eurogentec, an FDA inspected contract development and manufacturing organization announced today that its mRNA manufacturing facility has successfully produced a 25 g batch of mRNA for a US customer. Eurogentec’s GMP mRNA manufacturing service offers in vitro transcription (IVT), purification, quality control and batch release of GMP material up to 25 g scale in its current facility in Belgium. In this project Eurogentec successfully produced and purified 25 g of mate...

Read More

Cell and Gene Therapy, Industrial Impact

GENSCRIPT PROBIO ENTERS INTO STRATEGIC PARTNERSHIP WITH RVAC MEDICINES

GenScript ProBio | February 24, 2023

news image

GenScript ProBio, a renowned Contract Development and Manufacturing Organization (CDMO), has recently entered a strategic partnership agreement with RVAC Medicines Pte. Ltd., a biotech company specializing in the development and commercialization of mRNA vaccines and therapeutics. The collaboration is aimed at manufacturing GMP-grade plasmid DNA (pDNA) for the RVM-V001 mRNA COVID-19 vaccine candidate, as well as supporting future therapeutic pipelines. GenScript ProBio will offe...

Read More

Cell and Gene Therapy

VAXART ANNOUNCES HIGHLY REGARDED BIOTECH EXECUTIVE ELAINE J. HERON, PH.D. JOINS BOARD OF DIRECTORS

Vaxart, Inc. | August 29, 2022

news image

Vaxart, Inc. announced that Elaine J. Heron, Ph.D. was appointed to the Company’s Board of Directors, effective August 25, 2022. "Elaine has tremendous experience in life science research and development, sales and marketing, finance, and accounting, as well as corporate governance matters,” said Andrei Floroiu, Vaxart's Chief Executive Officer. "We welcome Elaine to Vaxart and the Board.” The Company also announced that Dr. Julie Che...

Read More
news image

MedTech

FDA GRANTS ILIAD BIOTECHNOLOGIES FAST TRACK DESIGNATION FOR NEXT GENERATION PERTUSSIS VACCINE BPZE1

ILiAD Biotechnologies | January 04, 2022

ILiAD Biotechnologies, a late stage biotech development company focused on global eradication of disease due to Bordetella pertussis, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BPZE1, a next generation vaccine for active booster immunization against pertussis. BPZE1 is the most advanced next generation pertussis vaccine currently in clinical development. Developed in the laboratory of Camille Locht, PhD, at the Institut Pasteur...

Read More
news image

Cell and Gene Therapy

KANEKA EUROGENTEC ANNOUNCES THE SUCCESSFUL PRODUCTION OF 25G OF MRNA IN ONE BATCH

Kaneka Eurogentec | February 23, 2022

Kaneka Eurogentec, an FDA inspected contract development and manufacturing organization announced today that its mRNA manufacturing facility has successfully produced a 25 g batch of mRNA for a US customer. Eurogentec’s GMP mRNA manufacturing service offers in vitro transcription (IVT), purification, quality control and batch release of GMP material up to 25 g scale in its current facility in Belgium. In this project Eurogentec successfully produced and purified 25 g of mate...

Read More
news image

Cell and Gene Therapy, Industrial Impact

GENSCRIPT PROBIO ENTERS INTO STRATEGIC PARTNERSHIP WITH RVAC MEDICINES

GenScript ProBio | February 24, 2023

GenScript ProBio, a renowned Contract Development and Manufacturing Organization (CDMO), has recently entered a strategic partnership agreement with RVAC Medicines Pte. Ltd., a biotech company specializing in the development and commercialization of mRNA vaccines and therapeutics. The collaboration is aimed at manufacturing GMP-grade plasmid DNA (pDNA) for the RVM-V001 mRNA COVID-19 vaccine candidate, as well as supporting future therapeutic pipelines. GenScript ProBio will offe...

Read More
news image

Cell and Gene Therapy

VAXART ANNOUNCES HIGHLY REGARDED BIOTECH EXECUTIVE ELAINE J. HERON, PH.D. JOINS BOARD OF DIRECTORS

Vaxart, Inc. | August 29, 2022

Vaxart, Inc. announced that Elaine J. Heron, Ph.D. was appointed to the Company’s Board of Directors, effective August 25, 2022. "Elaine has tremendous experience in life science research and development, sales and marketing, finance, and accounting, as well as corporate governance matters,” said Andrei Floroiu, Vaxart's Chief Executive Officer. "We welcome Elaine to Vaxart and the Board.” The Company also announced that Dr. Julie Che...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us